Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
Study Identifier:
ALXN1720-MG-301
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Recruitment Complete
Study Details
Medical Condition
- Unmapped
Study Drug
Date
Nov 2022 - May 2025
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years
Study Details
Medical Condition
- Unmapped
Study Drug
Date
Nov 2022 - May 2025
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information
Protocol Summary
The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine receptor (AChR).
Trial Locations
Location
Status
Location
Research Site
Orange, California, United States, 92868
Status
N/A
Location
Research Site
Fort Collins, Colorado, United States, 80528
Status
N/A
Location
Research Site
Washington, District of Columbia, United States, 20007
Status
N/A
Location
Research Site
Bradenton, Florida, United States, 34209
Status
N/A
Location
Research Site
Maitland, Florida, United States, 32751
Status
N/A
Location
Research Site
Tampa, Florida, United States, 33612
Status
N/A